Abstract:We previously found that the levels of metabolite N-acetylglutamine were significantly increased in urine samples of patients with heart failure (HF) and in coronary artery ligation (CAL)-induced HF mice, whereas the expression of its specific metabolic-degrading enzyme aminoacylase-1 (ACY1) was markedly decreased. In the current study, we investigated the role of ACY1 in the pathogenesis of HF and the therapeutic effects of 20(S)-ginsenoside Rg3 in HF experimental models in vivo and in vitro. HF was induced in mice by CAL. The mice were administered Rg3 (7.5, 15, 30 mg · kg−1· d−1, i.g.), or positive drug metoprolol (Met, 5.14 mg · kg−1· d−1, i.g.), or ACY1 inhibitor mono-tert-butyl malonate (MTBM, 5 mg · kg−1 · d−1, i.p.) for 14 days. We showed that administration of MTBM significantly exacerbated CAL-induced myocardial injury, aggravated cardiac dysfunction, and pathological damages, and promoted myocardial fibrosis in CAL mice. In Ang II-induced mouse cardiac fibroblasts (MCFs) model, overexpression of ACY1 suppressed the expression of COL3A1 and COL1A via inhibiting TGF-β1/Smad3 pathway, whereas ACY1-siRNA promoted the cardiac fibrosis responses. We showed that a high dose of Rg3 (30 mg · kg−1· d−1) significantly decreased the content of N-acetylglutamine, increased the expression of ACY1, and inhibited TGF-β1/Smad3 pathway in CAL mice; Rg3 (25 μM) exerted similar effects in Ang II-treated MCFs. Meanwhile, Rg3 treatment ameliorated cardiac function and pathological features, and it also attenuated myocardial fibrosis in vivo and in vitro. In Ang II-treated MCFs, the effects of Rg3 on collagen deposition and TGF-β1/Smad3 pathway were slightly enhanced by overexpression of ACY1, whereas ACY1 siRNA partially weakened the beneficial effects of Rg3, suggesting that Rg3 might suppress myocardial fibrosis through ACY1. Our study demonstrates that N-acetylglutamine may be a potential biomarker of HF and its specific metabolic-degrading enzyme ACY1 could be a potential therapeutic target for the prevention and treatment of myocardial fibrosis during the development of HF. Rg3 attenuates myocardial fibrosis to ameliorate HF through increasing ACY1 expression and inhibiting TGF-β1/Smad3 pathway, which provides some references for further development of anti-fibrotic drugs for HF.

Rg3 promotes the SUMOylation of SERCA2a and corrects cardiac dysfunction in heart failure

The Pharmacological Mechanisms Underlying the Protective Effect of Ginsenoside Rg3 against Heart Failure

Ginsenoside Rg3 Improves Cardiac Function after Myocardial Ischemia/Reperfusion Via Attenuating Apoptosis and Inflammation

Ginsenoside Rb3 Regulates Energy Metabolism and Apoptosis in Cardiomyocytes Via Activating PPARα Pathway.

Ginsenoside Rb1 ameliorates heart failure through DUSP-1-TMBIM-6-mediated mitochondrial quality control and gut flora interactions

Ginsenoside Rg1 treats chronic heart failure by downregulating ERK1/2 protein phosphorylation

Ginsenoside Rb2 improves heart failure by down-regulating miR-216a-5p to promote autophagy and inhibit apoptosis and oxidative stress

Ginsenoside Rg1 attenuates mechanical stress-induced cardiac injury via calcium sensing receptor-related pathway

Ginsenoside Rg1 Ameliorates Rat Myocardial Ischemia-Reperfusion Injury by Modulating Energy Metabolism Pathways

Ginsenoside Rg1 Protects Rat Cardiomyocyte from Hypoxia/reoxygenation Oxidative Injury Via Antioxidant and Intracellular Calcium Homeostasis.

20(S)-ginsenoside Rg3 exerts anti-fibrotic effect after myocardial infarction by alleviation of fibroblasts proliferation and collagen deposition through TGFBR1 signaling pathways

Notoginsenoside R1 attenuates ischemic heart failure by modulating MDM2/β arrestin2-mediated β2-adrenergic receptor ubiquitination

Activation of ULK1 to trigger FUNDC1-mediated mitophagy in heart failure: Effect of Ginsenoside Rg3 intervention

Ginsenoside Rg1 Prevents Doxorubicin-Induced Cardiotoxicity Through The Inhibition Of Autophagy And Endoplasmic Reticulum Stress In Mice

Aminoacylase-1 plays a key role in myocardial fibrosis and the therapeutic effects of 20(S)-ginsenoside Rg3 in mouse heart failure

Ginsenoside Rg3 Improves Cardiac Mitochondrial Population Quality: Mimetic Exercise Training

Ginsenoside Rg5 Increases Cardiomyocyte Resistance to Ischemic Injury Through Regulation of Mitochondrial Hexokinase-Ii and Dynamin-Related Protein 1.

Ginsenoside Rg2 Alleviates Myocardial Fibrosis by Regulating TGF-β1/Smad Signalling Pathway

Ginsenoside Rg3 Attenuates Myocardial Ischemia/Reperfusion Injury Via Akt/Endothelial Nitric Oxide Synthase Signaling and the B-Cell Lymphoma/B-Cell Lymphoma-Associated X Protein Pathway

Ginsenoside Rb3 upregulates sarcoplasmic reticulum Ca 2+ -ATPase expression and improves the contractility of cardiomyocytes by inhibiting the NF-κB pathway

Ginsenoside Re Improves Isoproterenol-Induced Myocardial Fibrosis and Heart Failure in Rats